US equities |
MU $931.24 ▲+1.87% NVDA $217.23 ▼-1.84% SNDK $1,394.83 ▼-0.61% AMD $562.23 ▼-1.50% SPCX $148.62 ▼-2.33% INTC $95.37 ▼-2.80% AAPL $342.00 ▼-0.28% MSFT $539.44 ▲+1.08%
FinancialContent

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.8137 -0.0263 (-3.13%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming Scientific Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming October Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
Via Chartmill
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
Via Chartmill
News headline image
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗
Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive... 
Via MarketBeat
News headline image
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming September Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in... 
Via MarketBeat
News headline image
Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
Gene therapy developer advances three Phase III programs toward 2028 regulatory filings. 
Via The Motley Fool
Topics Earnings Retirement
News headline image
Ocugen Q2 Earnings Call Highlights ↗
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT... 
Via MarketBeat
Topics Earnings
News headline image
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming August Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗
Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis... 
Via MarketBeat
News headline image
Ocugen to Participate in Upcoming July Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Upcoming June Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Includes Full Exercise of $15.0 million Over-Allotment Option 
From Ocugen
Via GlobeNewswire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >